Zoledronate Increases Bone Mineral Density in Nonambulant Children With Cerebral Palsy: A Randomized Controlled Trial
Authors' conclusion
Zoledronate for 12 months increased BMD Z-scores significantly without affecting growth, but first-dose side effects were common and considerable. Studies into lower first doses and long-term outcomes are needed.
Study context
- Population
- Nonambulant children with CP aged 5 to 16 yearsall completed
- Participants
- 24 children
- Comparison
- Zoledronate vs placebo
- Zoledronaten = 14
- Primary endpoint
- BMD Z-score change at the lumbar spine and lateral distal femur (DXA)
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Lumbar spine BMD Z-score change · 12 months
Zoledronate
0.8
mean · CI 0.4–1.2 · SD
Placebo
0.0
mean · CI −0.3–0.3 · SD
Further findings
- Growth parameters similar in both groups
Safety
- Severe acute phase symptoms · after the first dose only · reported exclusively after the first dose — Zoledronate
- 50%
Original publication
Zoledronate Increases Bone Mineral Density in Nonambulant Children With Cerebral Palsy: A Randomized Controlled Trial. J Clin Endocrinol Metab. Published 26 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →